Lilly backs a $25M round for anti-inflammatory startup Symic

Damian Garde

San Francisco's raised $ 25 million to fund its work on a pair of anti-inflammatory medicines targeting the extracellular matrix, recruiting Eli to lead the as it works through clinical development.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS